Video

Expert Discusses Challenges of Treating Individuals at Large Cancer Centers

Conference|NANETS Annual Multidisciplinary NET Medical Symposium - North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses the challenges of treating neuroendocrine tumors in large cancer centers.

In a Pharmacy Times® interview, Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, about her presentation on neuroendocrine tumor (NETs) management in large cancer centers at the NANETS 2021 Conference.

She discussed the challenges of treating NETs in large cancer centers.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Pharmacy Times OPC
Related Content
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025

ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC

Christopher Danes, PhD Alana Hippensteele, Lead Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Visualization of lungs with tumors | Image Credit: © Alexej - stock.adobe.com
June 25th 2025

Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC

Alexandra Gerlach, Associate Editor
ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas
June 25th 2025

ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas

Jaume Capdevila, MD, PhD Alana Hippensteele, Lead Editor